1. Opening statement

Antiretroviral therapy (ART) has converted HIV infection from an almost universally fatal illness to a chronic manageable disease. Adherence to therapy is essential for full viral suppression and optimal immune reconstitution. If antiretroviral (ARV) drug levels are suboptimal, the risk of developing ARV drug resistance is high due to the high rate of HIV replication and the lack of proofreading capacity in the viral reverse transcriptase enzyme. Continuation of a failing ART regimen can affect both the treated individual and the community, as resistant viral strains can be transmitted to other persons.

Resistance can be minimised by uninterrupted supply of medication, scientifically sound prescribing practices, long-term adherence support, viral load (VL) monitoring, and rapid responses to demonstrated virological failure with timely changes of therapy.

Following the rapid scale-up of the programme for universal access to antiretroviral therapy (ART) in southern Africa, resistance to antiretroviral medications will occur. A detectable viral load must be treated as an emergency and should trigger intensive patient tracking and adherence counselling. In contrast to the developed world, the incidence of transmitted resistance is still low in most areas in the region. Therefore, in this consensus statement we do not recommend resistance testing in HIV-infected adults upon diagnosis or ART initiation. However, baseline resistance testing is recommended for children who have been exposed to ART for prevention of mother-to-child-transmission therapy and subsequently become HIV-infected. Resistance testing is also recommended after virological failure of first- and second-line ART regimens.

2. Recommendations for ARV drug resistance testing

2.1 The diagnosis of HIV in children aged <2 years

Genotyping at baseline to detect resistance mutations should be performed for all HIV-infected infants who have been exposed to any form of ART taken by the mother or infant for the prevention of mother-to-child transmission (PMTCT) of HIV, or who have unknown exposure to PMTCT. Infants and children are a challenging group to treat with ART, especially in resource-constrained healthcare settings. Children and their mothers are likely to have been exposed to ARV medications in PMTCT...
programmes. Approximately 52.6% (95% confidence interval (CI) 37.7 - 67.0) of children who fail PMTCT therapy have at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation after single-dose nevirapine (sdNVP), and about 16.5% (CI 8.9 - 28.3) after sdNVP combined with antepartum, postpartum or postnatal zidovudine (AZT) with or without lamivudine (3TC). These mutations will generally have disappeared, or may not be detectable by routine resistance testing, 2 years after the last dose of prophylactic ART. Children aged <3 years are treated with a boosted protease inhibitor (PI) regimen, but it is important to document NNRTI resistance, as this will have implications in the choice of second-line regimens. Resistance mutations in children failing ART seem to be more common than in adults. Results from baseline resistance testing will ensure the most appropriate selection of ARV drugs. Further research on appropriate drug regimens in paediatric and adolescent populations is, critically, an unmet need.

2.2 Failure of ARV regimens
Resistance testing is recommended for all patients (children and adults) failing first-line NNRTI-based ARV regimens, with failure defined as two VL measurements >1 000 RNA copies/ml, with adherence and other issues addressed in the interval (see section 5). The accumulation of resistance mutations can be minimised by repeating the VL measurement within 3 months. If the first-line regimen is fully effective, then the VL should have fallen by 1.0 log₁₀ copies/ml within 4 weeks or be undetectable by 3 months (or <1 000 RNA copies/ml in patients whose initial VL was very high).

Resistance tests serve two purposes: (i) a fully sensitive pattern may imply that the patient is not adhering to treatment or has completely interrupted ART; and (ii) if resistance mutations are present, then the clinician, preferably together with an expert, can decide on the most appropriate second-line regimen. In patients on a stavudine (d4T)- or AZT-containing NNRTI-regimen, or on a tenofovir (TDF)-containing regimen, the importance of excluding resistance to TDF is crucial. TDF may be required as part of the nucleoside reverse transcriptase inhibitor (NRTI) backbone in second-line ART, or for treatment of hepatitis B virus (HBV)/HIV co-infection in combination with 3TC.

Resistance testing is recommended for all patients (children and adults) failing a PI-based ARV regimen. Failure is defined as two VL measurements >1 000 RNA copies/ml, with measurements taken 3 - 6 months apart and with adherence and other issues addressed in the interval. An absence of PI mutations during PI-based therapy strongly suggests non-adherence to treatment. Children on any PI regimen are at high risk for PI resistance if co-treated with rifampicin (for tuberculosis). Repeated VL measurements and resistance testing are recommended for patients failing long-term PI regimens with a concurrent decline in CD4 count.

2.3 Acute infection
Recent HIV infection in adults is rarely documented; however, viral genotyping at this time may give valuable public health insights into currently circulating strains. Resistance testing recommendations for specific acute infection scenarios are shown in Table 1.

3. Scenarios where ARV resistance testing is not recommended

3.1 HIV diagnosis in adults and adolescents
At the current level of transmitted resistance in the community, performing resistance testing in all individuals who are diagnosed with HIV infection is not cost-effective.

For pregnant women, although we do not recommend routine resistance testing, we do recommend HIV VL testing 3 months after initiating triple ARV therapy (for CD4 counts <350 cells/mm³) or at the time that pregnancy is confirmed in women already receiving ART. A VL >1 000 RNA copies/ml at this point should be regarded as an emergency, and should lead to intensive adherence support and screening for drug interactions or other reasons for failure (section 5), to minimise fetal transmission risk. The VL measurement should be repeated after 4 weeks, and, if >1 000 copies/ml, HIV resistance testing and an immediate switch to a second-line ART regimen must be performed.

3.2 ARV initiation in adults and children aged >2 years
Children aged >2 years who stopped taking prophylactic NVP during breastfeeding more than 2 years previously do not need a resistance test prior to ARV initiation. In such cases, resistance, if present, is very unlikely to be detected by genotyping. While super-infection with a resistant viral strain is a theoretical possibility, it is considered to be so rare that performing resistance tests would not be cost-effective.

3.3 Treatment interruptions without documented failure
Patients who have interrupted therapy for reasons other than proven virological failure should not have HIV genotype testing performed upon presentation for subsequent ART. Rather, the previous ART regimen should be re-started, and VL should be measured after 3 months. Resistance mutations generally disappear rapidly in the absence of drug pressure and a reliable resistance test result may not be obtained during treatment interruptions. If the VL is not suppressed after adherence intervention, a resistance test can be obtained to document resistance, and an appropriate second-line regimen can be selected.

4. National integration of public sector laboratories
In the public sector in South Africa, the NHLS has five centralised facilities capable of conducting sequence-based resistance testing. Currently, only two of these facilities perform routine genotyping for patient care on a large scale (Tygerberg and Johannesburg). Laboratories focus on genotyping assays, most using in-house assays, with backup from commercial assays such as Viroseq or TruGene. National surveillance is conducted at the NICD. As the ARV programme expands and patients receive treatment for longer periods of time, the capacity for resistance testing will need to be expanded. Currently, phenotyping capabilities for resistance are available, largely for research purposes, at several academic centres. Numerous research projects are underway to develop and assess more affordable and accessible approaches to resistance testing (e.g. sequencing short regions of the reverse transcriptase gene). The Southern Africa Treatment and Resistance Network (SATuRN) has integrated the efforts of laboratories, researchers and clinicians to monitor HIV resistance patterns and advise on the clinical management of patients failing ART. The SATuRN drug resistance database systems are freely available and include two of the best public drug resistance databases in the world: the Stanford HIV Drug Resistance database and the RegaDB Clinical Management Database. SATuRN databases are used to deliver an approach to virological failure, delivering resistance genotyping, interpretation and clinical management to remote primary healthcare clinics without elaborate computer systems or infectious diseases specialists at each clinic.
For each case, all laboratories (non-governmental, public and private) generate a report that includes clinical and resistance data. This report is sent to HIV specialists for review and feedback, to advise management at the primary clinic.

Meaningful interpretation of the results of genotypic resistance tests requires a detailed knowledge of the patient’s full ARV history, including drug regimens used, VL and CD4 test results, any previous resistance test results, co-occurrence of other infections, and timelines. This information needs to be provided by the clinician/nurse upon submitting the resistance test.

### 4.1 Surveillance of ARV drug resistance

The ongoing monitoring of ARV drug resistance is a critical public health activity, particularly in settings where individualised ARV drug resistance testing (genotyping) is not routinely performed prior to ART initiation. The success of empiric ART regimens depends on the regular and timely knowledge and review of the epidemiology of ARV drug resistance. Recommended systems for surveillance include prevalence monitoring of HIV genotype results at sentinel sites among populations who have recently acquired infection: e.g. recent seroconverters, HIV-infected pregnant women aged ≤21 years, infants infected despite ARV exposure and those with acute HIV infection. There may also be additional value in prevalence monitoring at sentinel sites of ARV drug resistance among those newly initiating therapy.

### 4.2 Monitoring and evaluation

The proportion of ART-treated patients on first-line, second-line and subsequent therapy should be monitored routinely. Because a

---

**Table 1. Recommendations for HIV resistance testing**

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Recommendation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recent infection</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infected infants aged &lt;2 years exposed to PMTCT or infected children aged &gt;2 years who stopped taking daily NVP less than 2 years previously</td>
<td>Recommended</td>
<td>As soon as HIV infection is diagnosed</td>
</tr>
<tr>
<td>Infants aged &lt;2 years where exposure to PMTCT is uncertain</td>
<td>Recommended</td>
<td>As soon as HIV infection is diagnosed</td>
</tr>
<tr>
<td>Documented acute infection* (seroconversion)</td>
<td>Recommended</td>
<td>Possible public health surveillance function</td>
</tr>
<tr>
<td><strong>HIV diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients without documented seroconversion presenting for routine clinical care</td>
<td>Not recommended</td>
<td>Background prevalence of transmitted resistance is low and time since infection is likely to be long, decreasing the likelihood of detecting resistance mutations</td>
</tr>
<tr>
<td><strong>ARV initiation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children aged ≥2 years about to start first-line ART</td>
<td>Not recommended</td>
<td>Unless within 2 years of stopping daily NVP</td>
</tr>
<tr>
<td>Pregnant women about to start first-line ART</td>
<td>Not recommended</td>
<td>Pregnant women should have a VL measurement 3 months after ART initiation. Detectable viraemia &gt;1 000 RNA copies/ml should be treated as an adherence emergency.</td>
</tr>
<tr>
<td>Adults about to start first-line ART</td>
<td>Not recommended</td>
<td>Background prevalence resistance is very low and the time since infection is likely to be long, decreasing the likelihood of detecting resistance mutations.</td>
</tr>
<tr>
<td><strong>Failure of NNRTI-based ART</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults and children with two VL measurements &gt;1 000 RNA copies/ml and/or at least a &lt;2 log₉ drop in VL while on NNRTI-based ART (measurements at least 4 weeks, preferably 3 months, apart)</td>
<td>Recommended</td>
<td>Adherence issues should be addressed comprehensively between the 2 measurements. Resistance testing should be performed while the patient is on the failing regimen or within 4 weeks of discontinuation.</td>
</tr>
<tr>
<td><strong>Failure of a boosted PI-based regimen</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults and children with two VL measurements &gt;1 000 RNA copies/ml and/or a &lt;2 log₉ drop in VL while on PI-based ART (measurements 3 - 6 months apart)</td>
<td>Recommended</td>
<td>Failure on PI regimens is almost always due to poor adherence. Adherence issues should be addressed comprehensively between the 2 measurements. Resistance testing should be performed while the patient is on the failing regimen or within 4 weeks of discontinuation.</td>
</tr>
</tbody>
</table>

PMTCT = prevention of mother-to-child transmission; NVP = nevirapine; ART = antiretroviral therapy; RNA = ribonucleic acid; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; VL = viral load.

*Some or all of the following features: high fever, generalised lymphadenopathy, oral ulcers, pharyngitis, maculopapular rash, lymphopenia, thrombocytopenia, and transaminases, in combination with a history suggestive of HIV exposure.

†Definition of virological failure may vary between southern African countries. A persisting VL of 500 - 1 000 copies/ml could be considered for resistance testing, with access to sensitive in-house assays.

‡See section on ARV adherence (section 5).
detectable plasma VL while on ART requires immediate intervention, national monitoring of the proportion of patients with detectable plasma VLS is recommended. Thresholds for response should be determined at the public health level. For example, a facility or geographic area with >20% detectable plasma viraemia in patients on ARV who were previously undetectable, should urgently be investigated. Analyses should be performed according to demographic and geographic characteristics, and reported quarterly to national HIV treatment programmes.

The evaluation of the effect of HIV genotype testing on the selection of ARV regimens and clinical outcomes should be supported through networks of clinical programmes. Indicators to monitor the use of HIV genotype resistance assays should include: the number of assays per specified time period; the proportion of assays performed in adults, children and pregnant women; and the prevalence and type of resistance (including class of resistance and specific mutations). As the surveillance of ARV resistance and clinical use of HIV genotyping increases, additional monitoring and evaluation activities may be required.

Most settings require increased capacity for monitoring and evaluation. Resources to sustain adequate data management and interpretation are a public health priority. The net cost of incorporating resistance testing, for surveillance as well as patient management, needs to be evaluated carefully in ARV programmes in southern Africa.14

5. Non-adherence: Causes and interventions
The adherence requirements of ART are onerous, necessitating adherence rates >90% for first-line NNRTI-based regimens. The best biological marker of adherence is an undetectable VL in patients on ART. The regularity of pharmacy pick-ups is also a good marker of adherence. Other strategies, including pill counts, have limited practical utility in busy clinics, and are often inaccurate.15 Pill boxes and treatment supporters may be useful in selected individuals.19 A detectable VL in patients on ART should be treated as a medical emergency, with immediate intervention, prompt evaluation by an experienced clinician and appropriate support staff (e.g. social workers, psychologists, and counsellors), and frequent follow-up. In the case of first-line virological failure, up to 50% of patients can re-suppress their VL,20 if virological failure is identified timely, and if adherence can be improved.

In patients failing second-line therapies, and where expensive third-line options are being evaluated, newer measures such as the use of electronic pill boxes (e.g. Medication Event Monitoring System (MEMS) caps) and hair PI levels may be used, if available.

In a significant minority of cases, patients will have no resistance on resistance testing. Data from South Africa reveal that this can be as high as 15 - 20% where patients have been genotyped.10,12 This means the patient is missing a large number of doses, consequently resulting in insufficient drug pressure to induce or select out existing resistance. These patients have a poorer prognosis, paradoxically, than patients with established resistance,11,13 as their poor adherence is often difficult to remedy, and may persist into subsequent regimen choices. Such patients often require the intervention of a psychologist or experienced counsellor.

Common causes of poor adherence (sections 5.1 - 5.12) are often complex and linked to social issues.

5.1 Inadequate treatment literacy
Most HIV programmes have extraordinary adherence rates when compared with other chronic diseases – largely due to efforts by clinic staff to ensure that patients understand HIV infection and ART. If a patient fails therapy, then some examination of the pre-ART counselling may be merited.

5.2 Side-effects
Side-effects are a very common reason for patients to default therapy. A careful history of often subtle but distressing side-effects (bad dreams, sleepiness, poor concentration, nausea, loss of appetite), in conjunction with a work history (shift work in particular) may allow for drug substitutions. Subtle signs of lipoatrophy due to NRTIs are often not taken seriously by healthcare providers. Regular enquiry and immediate drug substitutions should form part of every healthcare worker encounter. Single drug substitutions should only be performed if the VL is undetectable.

5.3 Depression and mental illness
Undiagnosed or under-treated depression and other mental illnesses are often overlooked. The frequency of major depression is twice as high in HIV-infected patients as in matched HIV-negative patients.21 Patients with depression usually respond well to treatment with an antidepressant in combination with other non-pharmaceutical interventions. Patients who respond to antidepressant medication should be treated accordingly for at least 6 months.

5.4 Poverty and food insecurity
Both poverty and food insecurity have been related to poor adherence and an increased frequency of missed clinic visits. Patients often lose their jobs due to ill health in the period leading up to ART initiation. Patients should be encouraged to return to the job market as soon as is feasible, or to seek support. The need to seek work may cause patients to move away from the current clinic; therefore, referral must be facilitated. Access to available grants, social support and employment NGOs may provide additional support.

5.5 Work-related issues
Work-related issues, including shift work and an inability to attend clinic visits on weekdays, are a major cause of poor adherence. Long clinic waiting times and monthly medication pick-ups, may make holding down a job untenable, especially with an unsympathetic employer.

5.6 Substance use
Alcohol use may cause significant problems with adherence. In addition, other recreational drugs may cause problems in certain parts of the country. Use may fluctuate according to availability and peer pressure.

5.7 Social problems
Social problems that affect adherence include stigma, both external and internal, and poor social support networks. Perceived stigma is correlated with poor adherence. This may manifest in: a fear of tablets being found; an inability to solicit family or partner support; fear around visiting the clinic or pharmacy; or anxiety regarding an employer, neighbours or a community. Social support groups may assist in this regard.

5.8 Denial
ART initiation in ambivalent, conflicted patients is unlikely to have a successful outcome. The involvement of family members and partners may be an effective mechanism for addressing denial.

5.9 Pill burden
Pill burden is less of an issue with current regimens, but must be considered in patients who are failing treatment. Pill burden due to treatment for other
conditions, such as hypertension or diabetes, should also be addressed. Dosing simplification, such as provision of fixed-dose combination regimens, where possible, should be a major part of advocacy within public programmes.

5.10 Altered fertility intentions
HIV-discordant or -concordant couples may spontaneously decide to cease their ART regimen with the intent to begin a family. Empathetic fertility counselling during ART initiation should prevent this from occurring.

5.11 Conflict of opinions
Conflict of opinions on the use of ARVs occurs frequently between healthcare providers, certain alternative health providers and churches. This is best addressed with an honest and non-judgmental conversation.

5.12 Other
Drug doses should be checked, especially in patients referred from the private sector or inexperienced sites. Drug interactions (e.g. rifampicin with a PI), absorption issues and primary acquisition of resistant virus may also result in failure.

6. Laboratory objectives

6.1 Recommendations and requirements
A meaningful interpretation of genotypic resistance test results requires detailed knowledge of the patient’s full ARV history, including drug regimens used, VL and CD4 test results, any previous resistance test results, and timelines.

It is desirable that national databases be built, using unique patient identifiers (e.g. ID numbers), to allow the easy retrieval of information for patients who have been cared for at different clinics and tested by different laboratories. Besides improving patient care and easing clinical workload, this approach is cost-effective, as it prevents unnecessary repeat testing.

All resistance test results (including clinical information and sequences obtained) should be entered into a central database, such as the one maintained by SATURN, to enable research and surveillance.

6.2 Genotypic ARV resistance testing: Practical issues
Testing requires ethylenediaminetetra-acetic acid (EDTA) whole blood or EDTA plasma (purple-top tubes). Alternatively, where established, dried blood spots (DBSs) may be used. To ensure sample integrity, whole-blood and plasma samples must be maintained and shipped cooled (4°C – fridge temperature) and reach the laboratory within 48 hours. For longer delays, whole-blood specimens must be centrifuged and the plasma stored at -20°C (frozen). Repeat freeze-thaw cycles must be avoided. DBSs can be maintained at room temperature for up to 4 weeks, and must be frozen at -20°C if the delay is longer than 4 weeks.

Current commercial tests have been licensed for specimens with a viral load of at least 1 000 RNA copies/ml. If DBSs are used, then the minimum usable VL is 2 000 - 5 000 RNA copies/ml. Nevertheless, many in-house assays can detect VLs of 500 - 1 000 RNA copies/ml. The probability of harbouring resistance in the VL range of 500 - 1 000 RNA copies/ml is only marginally less than in the 1 000 - 10 000 copies/ml range.21 The acquisition of additional mutations is not necessarily associated with incremental increases in VL.21

Once a failing ART regimen has been discontinued, most resistant viral variants quickly become undetectable. Samples must therefore be obtained while the patient is still on the failing regimen or very shortly after discontinuation (to a maximum of 4 weeks).

Current test methods do not detect minority resistant viral variants (quasi-species present at less than approximately 20% of the total population) or archived resistance.26

Even in the best hands, the rate of failure to amplify virus is 5 - 10%, so not all samples submitted to the laboratory will have a genotype result.

6.3 Genotypic ARV resistance assays
Currently available genotype tests evaluate only the viral reverse transcriptase and protease genes. Mutations in the genes encoding these enzymes underlie resistance to the NRTIs, NNRTIs and PIs.

Raltegravir (RAL),27,28 the first of the integrase strand-transfer inhibitors (INSTIs), is now registered in South Africa. Currently, no entry inhibitors – e.g. maraviroc (a CCR5 co-receptor inhibitor) or enfuvirtide (a fusion inhibitor) – have been registered. Future genotype tests will also need to incorporate these drug classes.

Current resistance testing is performed by means of polymerase chain reaction (PCR) amplification and sequencing/genotyping of the HIV-1 protease and reverse transcriptase genes, using commercial or validated in-house assays. The turnaround time of these assays is approximately 2 weeks. Current United States Food and Drug Administration (FDA)-approved commercial assays, including ViroSeq and Trugene, can be performed at a cost of approximately R5 000 per assay. In-house assays are about 50% cheaper. Results can provide data on the presence or absence of resistance mutations, with resistance mutations interpretable by drug resistance algorithms, many of which are available online.

7. Research priorities

7.1 Resistance assays
The main thrust of research activities remains the need to develop rapid, affordable, accessible resistance assays, including:
• advocacy to drive down current commercial assay costs
• the evaluation of innovative new testing approaches, e.g. the use of more cost-effective strategies such as allele-specific assays (e.g. M184V) to determine adherence
• improved logistics using creative approaches such as DBS technology
• national standardisation of technology and reporting across the country
• continual review to ensure the incorporation of new drug classes into assays
• integrase assays
• tropism assays for CCR5 inhibitors
• the constant evaluation of new testing platforms, e.g. ultra-deep sequencing strategies
• the suitability of assays for relevant local HIV subtypes.

7.2 Operational research activities

7.2.1 Laboratory-based activities
Laboratory-based activities should include:
• the upgrading and up-scaling of infrastructure, human resource skills, interpretation skills, and improved emergency reporting within and by the laboratory
• national data flow and reporting
• a monitoring and evaluation framework to evaluate the effect of the intervention
• ongoing cost-effectiveness modelling and analyses to assess cost-effectiveness
• ensured support for strengthened national surveillance activities (i.e. increased numbers processed in realtime).
Conflict of interest. All expert panel members and reviewers have completed and submitted conflict of interest disclosure forms. Disclosure information represents the previous 3 years (updated 13 October 2012) and pertains to relationships with pharmaceutical companies and medical aids. F Conradie has received research support from Bristol-Myers Squibb, Gilead, GlaxoSmithKline and Tibotec. She is also a consultant for Discovery Health. L Levin has received honoraria from Abbott, Aspen, Novagen, Optipharma and Viiv Healthcare for speaking engagements, and serves as a consultant to Optipharm and Discovery Health. G Meintjes has received honoraria from Sanofi-Aventis for speaking engagements. F Venter has received honoraria from Abbott, Adcock Ingram, Aspen, MSD and Janssen for speaking engagements. G Meintjes has received honoraria from Sanofi-Aventis for speaking engagements. F Venter has received honoraria from Abbott for a speaking engagement, and serves as a consultant to Discovery Health. D Spencer has received honoraria from Abbott, Adcock Ingram, Aspen, MSD and Janssen for speaking engagements. H Sunpath has received research support from Gilead Sciences. G van Zyl has received honoraria from Abbott for speaking engagements. F Venter has received support from Adcock Ingram to attend conferences and honoraria received from Abbott for speaking engagements. F Venter has received honoraria from Abbott for a speaking engagement, and serves as a consultant to Discovery Health. D Spencer has received honoraria from Abbott, Adcock Ingram, Aspen, MSD and Janssen for speaking engagements. A Basson, T de Oliveira, G Hunt, D Joel, M Papathannasopoulos, W Preiser, J Klausner, W Stevens, C Van Vuuren and D Wilson have no conflicts of interest to declare.

Acknowledgement. This work was supported and funded by the Southern African HIV Clinicians Society through an educational grant from Atlantic Philanthropies. The authors wish to acknowledge Lynsey Isherwood for her assistance in the development of this document.

References